We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe (GRAVITY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00525824
Recruitment Status : Completed
First Posted : September 6, 2007
Results First Posted : October 7, 2009
Last Update Posted : May 13, 2011
Sponsor:
Information provided by:
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of >20%

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Coronary Heart Disease Atherosclerosis Drug: Rosuvastatin (Crestor) Drug: Ezetimibe Drug: Simvastatin Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1743 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD
Study Start Date : August 2007
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Drug: Rosuvastatin (Crestor)
    10mg and 20 mg
  • Drug: Ezetimibe
    10 mg
  • Drug: Simvastatin
    40mg and 80 mg

Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value*100


Secondary Outcome Measures :
  1. Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value*100

  2. Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in TC = (Combination treatment value - Baseline value)/Baseline value*100

  3. Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in TG = (Combination treatment value - Baseline value)/Baseline value*100

  4. Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value*100

  5. Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value*100

  6. Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100

  7. Percent Change in TC/HDL-C After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100

  8. Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100

  9. Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value*100

  10. Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value*100

  11. Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment [ Time Frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward) ]
    Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value*100

  12. Percent Change in LDL-C After 6 Weeks Monotherapy [ Time Frame: Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward) ]
    Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value*100


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of >20
  • Patients will need to sign an informed consent before any visit procedures can be performed, including procedures for the optional genetic research and biomarker studies.
  • Patients must be 18 years or older and will be asked to stop taking any current cholesterol-lowering medications. Dietary counselling will be provided which will include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will be asked to follow

Exclusion Criteria:

  • Use of lipid lowering drugs and other prohibited concomitant medications. History of statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history of hypersensitivity to any components of ezetimibe.
  • Patients considered to be unstable by their physician after the following events:

a myocardial infarction, recent episode of unstable angina, myocardial revascularisation [percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure] or a transient ischaemic attack (TIA) or stroke and patients awaiting a planned myocardial revascularisation

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00525824


Locations
Layout table for location information
United States, Tennessee
Research Site
Brentwood, Tennessee, United States
Argentina
Research Site
Buenos Aires, Argentina
Brazil
Research Site
Sao Paulo, SP, Brazil
Chile
Research Site
Santiago, Chile
Colombia
Research Site
Brentwood, Colombia
Lithuania
Research Site
Brentwood, Lithuania
Netherlands
Research Site
Zwinderen, Netherlands
Peru
Research Site
Lima, San Isidro Lima, Peru
Venezuela
Research Site
Brentwood, Venezuela
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Christie M Ballantyne, MD FACP FACC Centre for Cardiovascular Disease Prevention
Study Chair: Margareta Grind, MD PhD FFPM Medicine and Sciences AstraZeneca
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Michael Cressman - Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT00525824    
Other Study ID Numbers: D356FC00003
First Posted: September 6, 2007    Key Record Dates
Results First Posted: October 7, 2009
Last Update Posted: May 13, 2011
Last Verified: May 2011
Keywords provided by AstraZeneca:
Hypercholesterolaemia
Coronary Heart Disease (CHD)
Atherosclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Atherosclerosis
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Hypercholesterolemia
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Hyperlipidemias
Dyslipidemias
 Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Simvastatin
Ezetimibe
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors